ArticleOncoTargets and therapy2022

FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib.

Chen Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.